Inozyme Pharma approves transaction bonuses for CFO and COO in connection with BioMarin merger

Inozyme Pharma, Inc.

CFO Sanjay Subramanian to receive $350k cash bonus upon merger close.
COO Dr. Matthew Winton to receive $320k cash bonus upon merger close.
Bonuses require continued employment through closing; paid within 30 days after close.
Compensation committee approved grants on May 30, 2025, per Merger Agreement with BioMarin.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.